Cue Biopharma (CUE) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cue Biopharma (CUE) has outperformed Stablecoin Development (SDEV) over the past year, losing 0.2% versus a loss of 55.9%. Over five years, CUE leads with a -94.0% price change compared with -99.9% for SDEV. Cue Biopharma is the larger company by market cap ($161.3 million vs $143.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | SDEV |
|---|---|---|
| Share price | $22.20 | $2.78 |
| Market cap | $161.27M | $143.87M |
| 1-day change | -1.38% | -14.46% |
| YTD return | +146.01% | -90.14% |
| 1-year return | -0.22% | -55.87% |
| 5-year return | -94.04% | -99.92% |
| EPS (TTM) | $-29.59 | $-21.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $99.75 |
| 52-week low | $4.98 | $0.78 |
| Distance from 52-week high | -51.21% | -97.21% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +296.40% | — |
| Average volume | 267.68K | 11.42M |
| Shares outstanding | 7.26M | 51.75M |
| Employees | 29 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed SDEV by 55.7 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
CUE vs SDEV FAQ
Which is bigger, Cue Biopharma or Stablecoin Development?
Cue Biopharma (CUE) is larger, with a market capitalization of $161.27M compared with $143.87M for Stablecoin Development (SDEV).
Which stock has performed better over the past year, CUE or SDEV?
CUE returned -0.22% over the past 12 months, compared with -55.87% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and Stablecoin Development in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.